Skip to main content

Table 2 TREX2 DNA methylation in tumor tissue and overall survival of cancer patients. Samples from the German laryngeal cancer study and TCGA cancer patients with the ICD10-code C32 for laryngeal cancer are shown. For TCGA laryngeal cancer patients, overall survival was also analyzed in relation to TREX2 mRNA expression (given as log2 (normalized expression + 1)). HRs with p values < 0.05 are presented in italic

From: DNA methylation at an enhancer of the three prime repair exonuclease 2 gene (TREX2) is linked to gene expression and survival in laryngeal cancer

Gene/CpG site in Amplicon TREX2_2 or on 450K array (TCGA studies)

Observations/events, N/N

Univariable analysisa

Adjusted for age and gendera

HR (95% CI)

p value

HR (95% CI)

p value

German larynx study

 CpG 1,2

181/112

0.713 (0.295–1.722)

0.4523

0.678 (0.278–1.654)

0.7289

 CpG 3,4

0.347 (0.120–1.002)

0.0505

0.339 (0.118–0.978)

0.0453

 CpG 5

1.197 (0.677–2.114)

0.5364

1.078 (0.606–1.918)

0.7984

  Average

0.657 (0.237–1.822)

0.4193

0.561 (0.198–1.592)

0.2776

TCGA laryngeal cancer cohort

 cg09364317

119/52

0.176 (0.032–0.980)

0.0473

0.106 (0.017–0.686)

0.0184

 cg18879010

0.146 (0.017–1.257)

0.0798

0.207 (0.022–1.935)

0.1673

TREX2 mRNA expression

118/52

0.766 (0.625–0.939)

0.0104

0.726 (0.589–0.895)

0.0027

  1. aHazard ratios (HRs) and 95% confidence interval (CI) for continuous change of methylation after univariate analysis and adjusted for age and gender